Popular Articles

Genetic Immunity, InPlay Completes Patient Enrollment In Phase II Trial Of DermaVir Patch HIV Immunotherapeutic Nanomedicine Lead Product Candidate
Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary"s premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis.
buy viagra
Commercial Manufacturing Of H1N1 'Swine Flu' Vaccine Underway
Protein Sciences Corporation (PSC) announced that it commenced manufacturing of a vaccine to protect humans against the H1N1 "swine flu" virus. The Company estimates that it can produce 100,000 doses this week and at least 100,000 doses per week thereafter. The vaccine, called PanBlok(R), is made using PSC"s proprietary baculovirus and insect cell manufacturing technology. PSC believes that PanBlok is the first and only vaccine that could be used to protect against the escalating worldwide pandemic, at least for the next few months.
plan for health
News of the day
Public Health

MDS Nordion Opens New Radiopharmaceutical Production Facility In Belgium

MDS Nordion, a leading global provider of medical isotopes and radiopharmaceuticals used in molecular medicine, today announced the opening of a facility in Fleurus, Belgium for the production of Fluorodeoxyglucose (F-18 FDG), a radiopharmaceutical used in positron emission tomography (PET) imaging. PET imaging produces a three-dimensional image, or picture, of functional processes in the body, such as brain activity, and is a highly accurate and effective method of diagnosing disease and managing patient therapy. MDS Nordion"s new facility will provide timely supply of F-18 FDG to hospitals throughout Belgium, France, The Netherlands, Luxembourg and Germany. "Customers count on MDS Nordion for leadership, quality products and customized services," said Steve West, President MDS Nordion. "Our investment in this facility further demonstrates our commitment to address the growing demand for PET diagnostic imaging in targeted European regions, and provides the medical community greater service for their future patient care." The PET imaging market is the most rapidly growing area of nuclear medicine and procedures. Statistics from a recent Medical Options survey indicates PET examinations are on a rapid rise in Europe, and are expected to grow at a compound annual rate of approximately 20% through 2012. To help meet increasing demand, this state-of-the-art, Good Manufacturing Practice (GMP) production facility will have three daily production runs and a customer service team available 24 hours a day, seven days a week. "PET imaging is effective because it allows early detection of tumours, as well as assessment of therapeutic strategies," said Professor Roland Hustinx, Nuclear Medicine Department, CHU - Universite de Liege. "In particular, MDS Nordion"s new facility will provide another of supply of F-18 FDG to existing and new medical facilities, thereby increasing the ability of health-care practitioners to conduct this critical type of imaging." MDS Nordion


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):